Ai In Pharmacovigilance Market: Market Size & Forecast 2026

AI in pharmacovigilance involves the application of machine learning, natural language processing, and related technologies to automate the collection, detection, assessment, and monitoring of adverse drug reactions and product safety issues. The global market reached approximately $680 million in 2025 and is currently estimated at approximately $0.779 billion in 2026, with industry analyses projecting a compound annual growth rate of 14.6% through 2031. This segment operates within the broader global pharmacovigilance market, which reached approximately $9.35 billion in 2025 and is growing at a comparable pace.

The pharmaceutical industry faces mounting pressure to automate adverse event processing as data volumes surge from electronic health records, social media, scientific literature, wearable devices, and patient-reported sources. Regulatory authorities worldwide are mandating more robust and timely safety reporting, compelling drug manufacturers and contract research organizations to adopt scalable AI solutions that can handle complex, multi-source data. Additionally, the substantial cost and time savings achievable through AI-driven automation compared to manual pharmacovigilance workflows represent strong economic incentives for continued investment.

The market is commonly segmented by component into software platforms and professional services, by deployment model into cloud-based and on-premise solutions, and by application into adverse event case processing, signal detection, and literature monitoring. Geographically, North America currently leads the market due to stringent FDA reporting requirements, high pharmaceutical R&D spending, and advanced healthcare IT infrastructure. Europe follows closely as a mature market, while the Asia-Pacific region is expected to exhibit the fastest growth trajectory as local regulatory frameworks evolve and pharmaceutical manufacturing and research activities expand.

What are the recent trends and outlook?

Natural language processing is becoming increasingly sophisticated at extracting adverse event information from unstructured sources such as social media posts, patient forums, and biomedical literature, expanding the scope of pharmacovigilance beyond traditional spontaneous reporting systems. Real-world evidence integration is gaining prominence, with AI systems correlating electronic health records, claims data, and wearable device outputs to detect safety signals earlier in the product lifecycle and support benefit-risk assessments. Looking ahead, the convergence of generative AI, multi-modal data analysis, and regulatory technology is expected to further accelerate market adoption and reshape drug safety operations through 2031.